GCP
NAMS icon

GSA Capital Partners’s NewAmsterdam Pharma NAMS Stock Holding History

GSA Capital Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,358
Closed -$458K – 2005
2025
Q1 		$458K Sell
22,358
-31,877
-59% -$709K 0.04% 860
2024
Q4 		$1.39M Sell
54,235
-12,167
-18% -$258K 0.1% 224
2024
Q3 		$1.1M Buy
66,402
+29,496
+80% +$510K 0.08% 416
2024
Q2 		$709K Buy
+36,906
New +$740K 0.05% 744

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GSA Capital Partners's NAMS Position: Q2 2025 in Review

GSA Capital Partners sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 22,358 shares — an estimated $458K sold.

GSA Capital Partners first reported a position in NAMS in Q2 2024 and held it in 4 quarters. The position peaked at $1.39M in Q4 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

  • GSA Capital Partners reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 22,358 NewAmsterdam Pharma shares in Q2 2025, an estimated $458K.
  • GSA Capital Partners first reported a position in NewAmsterdam Pharma in Q2 2024 and held it in 4 quarters.
  • GSA Capital Partners's NewAmsterdam Pharma position peaked at $1.39M in Q4 2024.
  • 131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.